ENGN
NASDAQ · Biotechnology
Engene Holdings Inc
$7.21
-0.01 (-0.07%)
Open$7.19
Previous Close$7.22
Day High$7.48
Day Low$7.10
52W High$12.25
52W Low$2.65
Volume—
Avg Volume285.1K
Market Cap711.38M
P/E Ratio—
EPS$-2.29
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+806.1% upside
Current
$7.21
$7.21
Target
$65.33
$65.33
$48.23
$65.33 avg
$96.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 102.93M | 108.44M | 88.87M |
| Net Income | -18,276,199 | -22,730,064 | -15,420,094 |
| Profit Margin | -17.8% | -21.0% | -17.4% |
| EBITDA | -27,166,221 | -28,388,210 | -21,820,067 |
| Free Cash Flow | -19,844,248 | -21,752,544 | -13,746,863 |
| Rev Growth | +6.4% | +6.6% | +8.6% |
| Debt/Equity | 0.41 | 0.31 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |